Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed May 15, 2017 · 10-Q · 45 days after period end · 0001571049-17-005026
| Metric | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|
| Revenue | $303.14K | $994.89K | $494.89K |
| Net Income | -$8.05M | -$3.54M | -$13.98M |
| EPS Diluted | -$0.38 | -$0.32 | -$1.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Mar 31, 2017 · filed May 15, 2017 · 45 d after period end
